Last reviewed · How we verify
Cerebral embolism
Approved treatments
- Coumadin · Generic (originally Wisconsin Alumni Research Foundation)
Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis. - Dicuman · AbbVie
- Plavix · Generic (originally Sanofi/BMS)
Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cerebral embolism patent landscape — cliff calendar, originator estates, attackable patents
- Cerebral embolism treatment landscape brief
- Cerebral embolism treatment updates RSS
Frequently asked questions about Cerebral embolism
What drugs treat Cerebral embolism?
Tracked treatments include Coumadin, Dicuman, Plavix.
What is the treatment for Cerebral embolism?
Standard treatment for Cerebral embolism includes Coumadin, Dicuman, Plavix. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cerebral embolism patent cliff · Cerebral embolism CI report
- Treatment: Coumadin · Generic (originally Wisconsin Alumni Research Foundation)
- Treatment: Dicuman · AbbVie
- Treatment: Plavix · Generic (originally Sanofi/BMS)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing